Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$12.54 USD
+0.02 (0.16%)
Updated May 10, 2024 04:00 PM ET
After-Market: $12.55 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Zentalis Pharmaceuticals, Inc. [ZNTL]
Reports for Purchase
Showing records 61 - 69 ( 69 total )
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Phase 1 Monotherapy ZN-c3 Data at AACR 2021; Reit Buy and Raising PT to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; WEE1i ZN-c3 Ph 1 Data Ahead at AACR
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM and $65 PT; Enlightening Targeted Therapies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Steady Pipeline Progress: Phase 2 ZN-c5 Start in 1H21; Reit Buy and $43 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Emerging as a Platform Player in the Fast Growing Oral SERD Space; Initiate With Buy and $43 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A